Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aldesleukin + interferon alfa-2a + fluorouracil
- Development stage
- Discontinued
- Lead developer
- European Organisation for the Research and Treatment of Cancer
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
This combination therapy, investigated by the European Organisation for Research and Treatment of Cancer (EORTC), consists of the antimetabolite fluorouracil (5-FU), the recombinant cytokine aldesleukin (interleukin-2), and interferon alfa-2a. It was primarily evaluated as an adjuvant treatment for patients with high-risk renal cell carcinoma (RCC) following surgical nephrectomy. Fluorouracil acts as a small molecule thymidylate synthase inhibitor, disrupting DNA synthesis and repair in tumor cells. Aldesleukin and interferon alfa-2a serve as immunomodulatory agents that stimulate T-cell and natural killer (NK) cell activity to enhance the immune system's ability to clear residual microscopic disease. The Phase 3 EORTC 30992 trial compared this triple combination to observation alone; however, the study concluded that the regimen did not significantly improve disease-free or overall survival in the adjuvant setting.
- Other names
- 5-FU + IL-2 + IFN-alphaAtzpodien regimenadjuvant IL-2, IFN-alpha, and 5-FU
02
Targets
TS (Thymidylate synthase)IL-2R (Interleukin-2/interleukin-15 receptor complex)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on aldesleukin + interferon alfa-2a + fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aldesleukin + interferon alfa-2a + fluorouracil.